FDA prepares disclosure rules for xenotransplantation
This article was originally published in Clinica
Clinical trials involving xenotransplantation may soon be subject to new public disclosure rules in the US. The FDA last week issued a proposal that would provide public access to most of the information on a trial's study design and safety information. The rule would also apply to trials involving gene therapy.